NewAmsterdam Pharma (NAMS) shares were down 1% on Thursday after reporting a Q1 net loss of $0.34 per diluted share, narrowing from a $1.06 loss a year earlier.
Analysts polled by FactSet expected a $0.50 loss.
Revenue for the quarter ended March 31 was $3 million, up from $1.4 million a year earlier.
Analysts expected $1.6 million.
The Dutch biopharmaceutical company had cash and equivalents of $808.5 million at end of Q1 compared with $834.2 million on hand on Dec. 31, 2024.
Price: 18.08, Change: -0.84, Percent Change: -4.44
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。